PIK3CA/AKT1/PTEN tumor alterations were detected in 24 patients (33.8%) receiving capivasertib–fulvestrant and in 22 patients (34.9%) receiving placebo–fulvestrant (Supplementary Table 1). Here, AKT1 is linked to neoplasm.